Skip to main content
. Author manuscript; available in PMC: 2011 Nov 15.
Published in final edited form as: Clin Cancer Res. 2010 Oct 4;16(22):5573–5580. doi: 10.1158/1078-0432.CCR-10-1453

Figure 1. Treatment schema.

Figure 1

A) The first 12 patients treated on this trial received standard RT/TMZ (black bar) and adjuvant TMZ (gray bars) with weekly CCI-779 (black arrows) given both during RT/TMZ and adjuvant TMZ. B) A second cohort of patients was treated with weekly CCI-779 only during RT/TMZ followed by adjuvant TMZ monotherapy. Blood samples were drawn for immune monitoring at 4 time points labeled I–IV as indicated by gray arrows.